User profiles for A. Balduzzi

Alberto Balduzzi

MD and Ph.D Student @PancreasVerona
Verified email at studenti.univr.it
Cited by 1077

The Miami international evidence-based guidelines on minimally invasive pancreas resection

…, F Cipriani, A Alseidi, MI D'Angelica, A Balduzzi… - Annals of …, 2020 - journals.lww.com
Objective: The aim of this study was to develop and externally validate the first evidence-based
guidelines on minimally invasive pancreas resection (MIPR) before and during the …

[HTML][HTML] Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated …

A Balduzzi, E Brivio, A Rovelli, C Rizzari… - Bone Marrow …, 2020 - nature.com
Italy is the second exposed country worldwide, after China, and Lombardia is the most
affected region in Italy, with more than half of the national cases, with 13% of whom being …

[HTML][HTML] Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

…, N Boissel, F Mechinaud, A Balduzzi… - … England Journal of …, 2018 - Mass Medical Soc
Background In a single-center phase 1–2a study, the anti-CD19 chimeric antigen receptor (CAR)
T-cell therapy tisagenlecleucel produced high rates of complete remission and was …

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

K Rejeski, M Subklewe, M Aljurf, E Bachy, A Balduzzi… - Blood, 2023 - ashpublications.org
Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR)
T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

[HTML][HTML] Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment

O Hrusak, T Kalina, J Wolf, A Balduzzi… - European Journal of …, 2020 - Elsevier
Introduction Since the beginning of COVID-19 pandemic, it is known that the severe course
of the disease occurs mostly among the elderly, whereas it is rare among children and young …

[HTML][HTML] Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial

…, SL Khaw, KL Davis, J Krueger, A Balduzzi… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic
leukemia (R/R B-ALL) experience increased risk of morbidity with each additional line of …

Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic …

A Balduzzi, MG Valsecchi, C Uderzo, P De Lorenzo… - The Lancet, 2005 - thelancet.com
Background The dismal prognosis of very-high-risk childhood acute lymphoblastic leukaemia
could be improved by allogeneic haemopoietic cell transplantation. We compared this …

Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome

…, R Rondelli, E Lanino, A Balduzzi… - Blood, The Journal …, 2002 - ashpublications.org
Chronic graft-versus-host disease (cGVHD) remains the major cause of late morbidity and
mortality after allogeneic hematopoietic stem cell transplantation (HSCT). However, only a few …

Imatinib for refractory chronic graft-versus-host disease with fibrotic features

…, G Gini, N Mordini, A Balduzzi… - Blood, The Journal …, 2009 - ashpublications.org
We previously reported that patients with fibrotic, chronic graft-versus-host disease (cGVHD)
have antibodies activating the platelet-derived growth factor receptor pathway. Because this …

[HTML][HTML] Children with cancer in the time of COVID‐19: an 8‐week report from the six pediatric onco‐hematology centers in Lombardia, Italy

…, A Biondi, M Massimino, A Balduzzi - Pediatric blood & …, 2020 - ncbi.nlm.nih.gov
To the Editor: This report assesses the impact of the COVID-19 pandemic on pediatric cancer
patients over an 8-week period elapsing from the day of the Italian outbreak (February 20, …